|
Beximco Pharmaceuticals Limited (BPL) is currently exporting a wide range of drugs covering all major therapeutic classes and dosage forms to more than 20 countries across the globe and plans to enter the US and European markets within 2008.
Talking to the Afsar Uddin Ahmed, FE Director (Commercial) of BPL, said 30 per cent of country's total pharmaceutical exports are met by BPL at present and soon the volume of export figure would increase.
Afsar said export potentiality of pharmaceutical sector is very great and in future this sector may play the leading role in the country's exports.
Afsar also said the pharmaceutical industry has developed in the country very significantly over the years and most of the drugs used in the country are locally produced.
Afasr, however, said basic raw materials and chemicals used in pharmaceutical products are imported from abroad, which is nearly 70 per cent.
BPL presently manufactures and markets high quality and cost-effective pharmaceutical product of 200 brands (in 327 dosage forms and strengths) using state-of the-art technology.
Senior Marketing Manager of BPL Rizvi Ul Kabir said with a turnover of US$ 50 million in 2005 BPL currently meets 10 per cent of local demand of pharmaceuticals.
Listed in London Stock exchange as the first Bangladeshi public limited company BPL presently exports to Germany, Singapore, Russia, Ukraine, Georgia, Iran, Pakistan, Kenya, Mozambique, Malaysia, Hong Kong, Taiwan, Thailand, South Korea, the Philippines, Cambodia, Vietnam, Myanmar, Nepal and Bhutan.
Rizvi said BPL received spot order worth US$ 52,000 at Bangladesh single country fair in Sri Lanka.
Rizvi also said six types of four generics drugs are now being exported to Sri Lanka and twenty-eight more drugs are on the card to get registration.
Talking to the FE Sri Lankan High commissioner in Bangladesh Gamini S. Munasinghe said Sri Lanka would import more pharmaceutical products from BPL as it maintains global standard in all aspects of production.
Talking to the FE Afsar Uddin Ahmed said BPL Research and Development (R&D) lab equipped with modern and sophisticated facilities has developed anti HIV, anti-cancer and anti-smoking drugs.
Afasr said after the completion of US$ 50 million project of establishing a new plant BPL expects to enter into US pharmaceutical market, the largest in the world, by 2008.
|